Altoida

OverviewSuggest Edit

Altoida develops and markets a healthcare platform and application for Alzheimer’s patients. Altoida Medical Device (AMD) is a class II medical device to screen and monitor cognitive outcomes. It supports neurologists to classify patients healthy, at risk, and with Mild Cognitive Impairment (MCI) as a digital biomarker.

TypePrivate
Founded2016
HQLuzern, CHMap
Websitealtoida.com

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2020)13(-7%)
Cybersecurity ratingAMore

Key People/Management at Altoida

Richard Fischer

Richard Fischer

Founder & CEO
Ioannis Tarnanas

Ioannis Tarnanas

Founder & CSO
Maximilian Buegler

Maximilian Buegler

Founder & CTO
Show more

Altoida Office Locations

Altoida has offices in Luzern and Suwanee
Luzern, CH (HQ)
Professuren der Kultur-und Sozialwissenschaftlichen Fakultät 31 Hirschengraben
Suwanee, US
4315 Alta Dr #1402
Show all (2)

Altoida Financials and Metrics

Summary Metrics

Founding Date

2016

Altoida total Funding

$7.5 m

Time since last funding

4 months ago

Altoida investors

Polytech Ventures, Philipp Stauffer, Fyrfly Venture Partners, Hikma Ventures, Grey Sky Venture Partners, M Ventures, Adrian Locher, VI Partners AG, Alpana Ventures
Show all financial metrics

Altoida Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

Learn more about about our premium products
SecurityScorecard logo

Altoida Online and Social Media Presence

Altoida's Trends

Embed Graph

Altoida News and Updates

January 14, 2020

Altoida Chief Science Officer Ioannis Tarnanas to Keynote at Worldwebforum

Altoida detects Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) up to ten years prior to onset using a tablet or smartphone – with 94% accuracy HOUSTON, Jan. 14, 2020 /PRNewswire/ -- Altoida, Inc. today announced that Chief Science Officer Ioannis Tarnanas has been...
May 30, 2019

Altoida Raises $6.3M Series A to Predict Alzheimer's Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality

HOUSTON, May 30, 2019 /PRNewswire/ -- Altoida Inc. today announced a $6.3 million round of venture capital financing to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians and researchers around the globe. Led by a team of...
May 30, 2019

Using augmented reality, Altoida is identifying the likely onset of neurodegenerative diseases

For the past nineteen years, Ioannis Tarnanas, the founder and chief scientific officer at Altoida, has been developing virtual and augmented reality tools to offer predictions about the onset of mental illness in older patients. The company, whose tools have been approved by the Food and Drug Admin…

 Altoida Frequently Asked Questions

  • When was Altoida founded?

    Altoida was founded in 2016.

  • Who are Altoida key executives?

    Altoida's key executives are Richard Fischer, Ioannis Tarnanas and Maximilian Buegler.

  • How many employees does Altoida have?

    Altoida has 13 employees.

  • Who are Altoida competitors?

    Competitors of Altoida include OptimizeRx, Nano and Docplexus.

  • Where is Altoida headquarters?

    Altoida headquarters is located at Professuren der Kultur-und Sozialwissenschaftlichen Fakultät 31 Hirschengraben, Luzern.

  • Where are Altoida offices?

    Altoida has offices in Luzern and Suwanee.

  • How many offices does Altoida have?

    Altoida has 2 offices.